| Ibrutinib resistance mechanisms and treatment strategies for B-cell lymphomas B George, S Mullick Chowdhury, A Hart, A Sircar, SK Singh, UK Nath, ... Cancers 12 (5), 1328, 2020 | 97 | 2020 |
| Targeting phosphatidylinositol 3 kinase-β and-δ for Bruton tyrosine kinase resistance in diffuse large B-cell lymphoma N Jain, S Singh, G Laliotis, A Hart, E Muhowski, K Kupcova, T Chrbolkova, ... Blood Advances 4 (18), 4382-4392, 2020 | 26 | 2020 |
| Integration of metabolomics and gene expression profiling elucidates IL4I1 as modulator of ibrutinib resistance in ABC-diffuse large B cell lymphoma F Choueiry, S Singh, A Sircar, G Laliotis, X Sun, E Chavdoula, S Zhang, ... Cancers 13 (9), 2146, 2021 | 19 | 2021 |
| Impact and intricacies of bone marrow microenvironment in B-cell lymphomas: from biology to therapy A Sircar, SM Chowdhury, A Hart, WC Bell, S Singh, L Sehgal, N Epperla International journal of molecular sciences 21 (3), 904, 2020 | 13 | 2020 |
| PRMT5 supports multiple oncogenic pathways in mantle cell lymphoma SL Sloan, F Brown, M Long, C Weigel, S Koirala, JH Chung, B Pray, ... Blood, 2023 | 10 | 2023 |
| Exploiting the fibroblast growth factor receptor-1 vulnerability to therapeutically restrict the MYC-EZH2-CDKN1C axis-driven proliferation in Mantle cell lymphoma A Sircar, S Singh, ZY Xu-Monette, KM Coyle, LK Hilton, E Chavdoula, ... Leukemia, 1-13, 2023 | 7 | 2023 |
| Transcriptional regulation of amino acid metabolism by KDM2B, in the context of ncPRC1. 1 and in concert with MYC and ATF4 E Chavdoula, V Anastas, AL Ferlita, J Aldana, G Carota, M Spampinato, ... bioRxiv, 2023.07. 07.548031, 2023 | 2 | 2023 |
| Fibroblast growth factor receptor-1 is a novel therapeutic target in mantle cell Lymphoma A Sircar, S Singh, KH Young, N Epperla, L Sehgal Cancer Research 83 (7_Supplement), 1422-1422, 2023 | 1 | 2023 |
| The epigenetic factor KDM2B alters the serine-glycine synthesis pathway and the one-carbon metabolism (SGOC) in triple-negative breast cancer E Chavdoula, V Anastas, A La Ferlita, J Aldana, A Sircar, MA Freitas, ... Cancer Research 82 (12_Supplement), 3019-3019, 2022 | 1 | 2022 |
| Multiomics Integration Elucidates Metabolic Modulators of Drug Resistance in Lymphoma F Choueiry, S Singh, X Sun, S Zhang, A Sircar, H Amber, L Alinari, ... bioRxiv, 2021.01. 07.425721, 2021 | 1 | 2021 |
| Epidermal growth factor-like 7 is a novel therapeutic target in mantle cell lymphoma C Goda, S Kolovich, A Rudich, M Karunasiri, R Kulkarni, G Rajgolikar, ... Experimental Hematology, 2023 | | 2023 |
| Uncovering the metabolic vulnerabilities in activated B cell diffuse large B cell lymphoma S Singh, F Choueiry, A Sircar, N Epperla, J Zhu, L Sehgal Cancer Research 83 (7_Supplement), 3689-3689, 2023 | | 2023 |
| Multiomics integration elucidates onco-metabolic modulators of drug resistance in lymphoma S Singh, F Choueiry, A Hart, A Sircar, J Zhu, L Sehgal Cancer Research 81 (13_Supplement), 2351-2351, 2021 | | 2021 |
| Role of the FGFR1-KDM2B-EZH2 signaling axis in bone-marrow microenvironment mediated tumor survival & drug resistance in Mantle cell lymphoma A Sircar, S Singh, G Laliotis, E Chavdoula, A Hart, PN Tsichlis, L Sehgal Cancer Research 81 (13_Supplement), 1114-1114, 2021 | | 2021 |
| Selection Strategy for Shortlisting Potential Candidates for the Development of Biosimilars A Sircara, P Guptab, B Panib, RS Thakurb, A Mittalb, P Anandb, ... | | |
| Biosimilars as Therapeutic Agents against Neurodegenerative Diseases-A Focus on Multiple Sclerosis A Sircar, B Pani, U Chaudhry pathophysiology 15, 6, 0 | | |
| Poster number 69 submitted by Anuvrat Sircar A Sircar, S Singh, G Laliotis, E Chavdoula, A Hart, PN Tsichlis, L Sehgal | | |
